GARDNER PHYLLIS

CIK 00012386464 companiesPALO ALTO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001238646

Recent Transactions

45 trades

Award
MIMEDX GROUP, INC.$MDXG
Common Stock
2023-06-13$4.95/sh+35,354→ 117,024 total
Award
MIMEDX GROUP, INC.$MDXG
Common Stock
2022-06-07$3.96/sh+44,191→ 81,670 total
Award
MIMEDX GROUP, INC.$MDXG
Common Stock
2021-05-27$10.26/sh+17,056→ 37,479 total
Award
MIMEDX GROUP, INC.$MDXG
Common Stock
2021-04-28$10.71/sh+4,084→ 20,423 total
Award
MIMEDX GROUP, INC.$MDXG
Common Stock
2021-04-28$10.71/sh+16,339→ 16,339 total
Award
CohBar, Inc.
Stock Option (Right to buy)
2021-04-26+200,000→ 200,000 total
Award
Revance Therapeutics, Inc.
Common Stock
2020-05-14+6,000→ 16,500 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2020-05-14+12,000→ 12,000 total
Award
Revance Therapeutics, Inc.
Common Stock
2019-05-09+4,500→ 10,500 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2019-05-09+9,000→ 9,000 total
Award
CohBar, Inc.
Stock Options (right to buy)
2019-02-08+200,000→ 200,000 total
Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−15,000→ 0 total
Disposition to Issuer
Corium International, Inc.
Common Stock
2018-11-27$12.50/sh−34,203→ 0 total
Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−12,000→ 0 total
Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−12,000→ 0 total
Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−15,000→ 0 total
Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−7,920→ 0 total
Award
Revance Therapeutics, Inc.
Common Stock
2018-05-10+3,000→ 6,000 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2018-05-10+6,000→ 6,000 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-16$2.55/sh+4,000→ 7,000 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-16$2.55/sh+1,333→ 8,333 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-16+1,333→ 0 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-16+4,000→ 0 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-16$31.51/sh−5,333→ 3,000 total
Award
Corium International, Inc.
Director Stock Option (Right to Buy)
2017-12-01+15,000→ 15,000 total
Exercise/Conversion
Corium International, Inc.
Common Stock
2017-08-21$2.12/sh+33,064→ 34,203 total
Exercise/Conversion
Corium International, Inc.
Director Stock Option (Right to Buy)
2017-08-21−33,064→ 0 total
Award
Revance Therapeutics, Inc.
Common Stock
2017-05-11+3,000→ 3,000 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2017-05-11+6,000→ 6,000 total
Award
Corium International, Inc.
Director Stock Option (Right to Buy)
2016-12-22+15,000→ 15,000 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2016-05-05+8,000→ 8,000 total
Award
Corium International, Inc.
Director Stock Option (right to buy)
2015-12-18+12,000→ 12,000 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2015-05-07+8,000→ 8,000 total
Exercise/Conversion
Corium International, Inc.
Director Stock Option (right to buy)
2015-03-27+1,139→ 0 total
Exercise/Conversion
Corium International, Inc.
Common Stock
2015-03-27$0.20/sh+1,139→ 1,139 total
Award
Corium International, Inc.
Director Stock Option (right to buy)
2014-12-04+12,000→ 12,000 total
Conversion
Revance Therapeutics, Inc.
Series E-3 Convertible Preferred Stock
2014-02-11−115,787→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-4 Convertible Preferred Stock
2014-02-11−47,252→ 0 total
Conversion
Revance Therapeutics, Inc.
Convertible Promissory Notes
2014-02-11−41,312→ 0 total
Exercise of In-Money
Revance Therapeutics, Inc.
Warrant to Purchase Common Stock
2014-02-11−12,839→ 0 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+402,934→ 402,934 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+41,312→ 444,246 total
Conversion
Revance Therapeutics, Inc.
Series E-1 Convertible Preferred Stock
2014-02-11−124,558→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-2 Convertible Preferred Stock
2014-02-11−115,337→ 0 total
Exercise of In-Money
Revance Therapeutics, Inc.
Common Stock
2014-02-11+12,839→ 457,085 total

Companies

Recent Filings

Address

C/O ESSEX WOODLANDS HEALTH VENTURES 335 BRYANT STREET, THIRD FLOOR

PALO ALTO, CA, 94301

View on SEC.gov